Annexon, Inc. (ANNX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.00-7.51%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ANNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ANNX — earnings miss
Dated 2026-08-12
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
Why it matters: This is the first planned test of vonaprument's effect on vision loss. A clear benefit would support the GA program.
Watch forARCHER II meets its Month 15 primary endpoint, with a clear benefit on vision loss versus the trial control.
Also watch forARCHER II misses the Month 15 primary endpoint or the result is delayed beyond Q4 2026.
Why it matters: A filing would show that Annexon moved from early FORWARD results to a U.S. review. A delay or filing issue would weaken that progress.
Watch forAnnexon submits the tanruprubart BLA to the FDA in Q4 2026, using U.S. and European FORWARD data.
Also watch forThe BLA is not submitted by the end of Q4 2026, or the FDA declines to accept it for review.
Why it matters: The results will show if this oral drug changes complement and hemolysis markers. The study is in patients with cold agglutinin disease.
Watch forThe CAD study shows lower complement and bilirubin markers. The changes are linked to drug exposure and food intake.
Also watch forThe study shows no clear drop in complement or bilirubin markers. Or, Annexon delays the update past fall 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $672 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,101 loss on $10,000 · 51.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.